Article
Oncology
Yan Hu, Si-Ying Ren, Ruo-Yao Wang, Chao Zeng, Ji-Na Li, Peng Xiao, Fang Wu, Feng-Lei Yu, Wen-Liang Liu
Summary: The study demonstrated that preoperative administration of chemoimmunotherapy for patients with resectable NSCLC is safe and feasible, with the majority of patients experiencing no serious complications or adverse reactions during treatment.
FRONTIERS IN ONCOLOGY
(2021)
Article
Cardiac & Cardiovascular Systems
Alejandra Romero Roman, Jose Luis Campo-Canaveral de la Cruz, Ivan Macia, Ignacio Escobar Campuzano, Santiago Figueroa Almanzar, Maria Delgado Roel, Carlos Galvez Munoz, Eva M. Garcia Fontan, Ignacio Muguruza Trueba, Laura Romero Vielva, Jose Ramon Cano Garcia, Elisabeth Martinez Tellez, Concepcion Partida Gonzalez, Marcelo Fernando Jimenez Lopez, Unai Jimenez Maestre, Roberto Mongil Poce, David Sanchez Lorente, Antonio Alvarez Kindelan, Mariano Provencio Pulla
Summary: The analysis evaluated perioperative outcomes of surgical resection following neoadjuvant treatment with chemotherapy plus nivolumab in resectable stage IIIA non-small-cell lung cancer. Results showed that surgical resection after chemotherapy plus nivolumab was safe, with high rates of complete resection, downstaging, and major pathological response. The perioperative morbidity and mortality rates were comparable to previous reports, indicating the feasibility of a minimally invasive approach.
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY
(2021)
Review
Oncology
Stephanie P. L. Saw, Boon-Hean Ong, Kevin L. M. Chua, Angela Takano, Daniel S. W. Tan
Summary: Despite the advancements in treatment for advanced non-small-cell lung cancer (NSCLC), there is a renewed interest in neoadjuvant strategies for early-stage NSCLC. These strategies, including targeted therapy and immunotherapy, have the potential to greatly impact survival outcomes for early-stage NSCLC patients.
Review
Cardiac & Cardiovascular Systems
Jay M. Lee, Masahiro Tsuboi, Alessandro Brunelli
Summary: New adjuvant immunotherapy using immune checkpoint inhibitors (ICIs) shows potential advantages in treating resectable NSCLC, including earlier treatment of micrometastatic disease, broad activation of immune response, and guidance for adjuvant therapy.
ANNALS OF THORACIC SURGERY
(2022)
Article
Oncology
Samuel Rosner, Joshua E. Reuss, Marianna Zahurak, Jiajia Zhang, Zhen Zeng, Janis Taube, Valsamo Anagnostou, Kellie N. Smith, Joanne Riemer, Peter B. Illei, Stephen R. Broderick, David R. Jones, Suzanne L. Topalian, Drew M. Pardoll, Julie R. Brahmer, Jamie E. Chaft, Patrick M. Forde
Summary: We present the 5-year clinical outcomes of neoadjuvant nivolumab in resectable non-small cell lung cancer, showing favorable recurrence-free survival (60%) and overall survival (80%) rates. Major pathological responses and tumor PD-L1 positivity are associated with improved recurrence-free survival. This study provides the longest follow-up data for neoadjuvant anti-PD-1 therapy in any cancer type.
CLINICAL CANCER RESEARCH
(2023)
Review
Oncology
Khaled Sanber, Samuel Rosner, Patrick M. Forde, Kristen A. Marrone
Summary: Immune checkpoint blockade (ICB) has shown improved outcomes in advanced non-small cell lung carcinoma (NSCLC). Utilizing ICB early in the disease course, particularly in the neoadjuvant setting prior to surgery, has been suggested to have advantages. Clinical trials have demonstrated improved pathological responses and longer event-free survival when neoadjuvant ICB is added to chemotherapy. However, many questions remain to be addressed, including the optimal duration of neoadjuvant therapy and the clinical management of residual disease and recurrence.
Article
Cardiac & Cardiovascular Systems
Nicholas R. Mayne, Alexandra L. Potter, Kashika Bharol, Alice J. Darling, Vignesh Raman, Christopher Cao, Xiao Li, Thomas A. D'Amico, Chi-Fu Jeffrey Yang
Summary: This study evaluated the perioperative outcomes and survival of patients with non-small cell lung cancer who underwent surgery after preoperative immunotherapy. The results showed that immunotherapy followed by surgery is safe and feasible, with similar short-term outcomes and overall survival compared to preoperative chemotherapy followed by surgery.
ANNALS OF THORACIC SURGERY
(2022)
Article
Oncology
Antonio Passaro, Ilaria Attili, Filippo de Marinis
Summary: The Oncology Grand Rounds series aims to help readers better apply the research findings published in the Journal of Clinical Oncology to patients in their own clinical practice. It includes case presentations, descriptions of diagnostic and management challenges, literature reviews, and suggested treatment approaches.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Cardiac & Cardiovascular Systems
Kaitlin McLaughlin, Kay See Tan, Joe Dycoco, Monica F. Chen, Jamie E. Chaft, Nikhil P. Mankuzhy, Andreas Rimner, Rania G. Aly, Rachel E. Fanaroff, William D. Travis, Mark Bilsky, Manjit Bains, Robert Downey, James Huang, James M. Isbell, Daniela Molena, Bernard J. Park, David R. Jones, Valerie W. Rusch
Summary: A multidisciplinary care paradigm, involving medical and radiation oncology, as well as spine neurosurgery, can improve surgical outcomes for Pancoast tumors. Spine neurosurgery allows for the resection of transverse processes and vertebral bodies. This treatment approach is associated with a high rate of R0 resection, complete response, and major pathologic response. The prognosis of cT3 and cT4 tumors is similar.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
(2023)
Review
Oncology
Lanyi Nora Chen, Alexander Z. Wei, Catherine A. Shu
Summary: The advent of immune checkpoint inhibition has led to the exploration of neoadjuvant immunotherapy in resectable non-small-cell lung cancer (NSCLC). Several phase II trials have demonstrated the benefits of neoadjuvant immunotherapy, either alone or in combination with radiation or chemotherapy. These trials have shown high rates of pathologic response and improved surgical outcomes. The CheckMate-816 trial definitively established the benefit of neoadjuvant chemoimmunotherapy over chemotherapy alone for resectable NSCLC.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2023)
Article
Pharmacology & Pharmacy
Xiaomin Wan, Xiaohui Zeng, Liubao Peng, Ye Peng, Qiao Liu, Lidan Yi, Xia Luo, Qijian Deng, Chongqing Tan
Summary: The study suggests that nivolumab plus ipilimumab may be more cost-effective compared to chemotherapy, especially at a WTP threshold of $100,000/QALY to $150,000/QALY. Body weight and overall survival hazard ratio are key variables influencing the cost-effectiveness ratio.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Oncology
Michael R. Conroy, Colum Dennehy, Patrick M. Forde
Summary: Only a minority of lung cancers are resectable at diagnosis, highlighting the need for new approaches to improve cure rates. Checkpoint inhibitor immunotherapy has shown promising results in advanced lung cancer and is being increasingly used in the neoadjuvant setting, but questions remain regarding optimal duration, biomarkers, response assessment, and combination with other therapies.
Article
Medicine, General & Internal
Heather Wakelee, Moishe Liberman, Terufumi Kato, Masahiro Tsuboi, Se-Hoon Lee, Shugeng Gao, Ke-Neng Chen, Christophe Dooms, Margarita Majem, Ekkehard Eigendorff, Gaston L. Martinengo, Olivier Bylicki, Delvys Rodriguez-Abreu, Jamie E. E. Chaft, Silvia Novello, Jing Yang, Steven M. M. Keller, Ayman Samkari, Jonathan D. D. Spicer
Summary: Among patients with resectable early-stage NSCLC, perioperative pembrolizumab improved event-free survival, major pathological response, and pathological complete response. The addition of pembrolizumab to neoadjuvant chemotherapy followed by surgery showed significant benefits compared to neoadjuvant chemotherapy alone followed by surgery.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Hengrui Liang, Chao Yang, Diego Gonzalez-Rivas, Yunpeng Zhong, Ping He, Hongsheng Deng, Jun Liu, Wenhua Liang, Jianxing He, Shuben Li
Summary: This study evaluated the oncological and surgical outcomes of sleeve lobectomy in NSCLC patients who received neoadjuvant IO+C. The IO+C group showed better tumor response and fewer complications compared to the chemotherapy group, with similar surgical outcomes. The IO+C group also had better results in terms of lymph nodes and lymph nodes positive for tumor cells.
TRANSLATIONAL LUNG CANCER RESEARCH
(2021)
Article
Pharmacology & Pharmacy
Xuezhi Hao, Aizong Shen, Bin Wu
Summary: The cost-effectiveness analysis of nivolumab plus ipilimumab for advanced non-small cell lung cancer showed that it is a cost-effective option in the United States but not in China. Sensitivity analyses confirmed the robustness of the results.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Cardiac & Cardiovascular Systems
Soh Hosoba, Toshiaki Ito, Makoto Mori, Riku Kato, Koh Kajiyama, Shogo Maeda, Yuji Nakai, Yoshihiro Morishita
Summary: This study describes the approach and perioperative outcomes of totally endoscopic isolated and concomitant surgical aortic valve replacement (AVR) using various valve types. The results demonstrate that endoscopic AVR can safely address concomitant valve diseases.
ANNALS OF THORACIC SURGERY
(2024)